Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

FDA

PharmaDrug (BUZZ.C) passed their potential cancer fighter, cepharanthine02HC1, the active ingredient in their oral drug PD-001, through preclinicals today.   The results of the test are good. It’s proven…
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has provided its official Written Response to the Company’s request for a Pre-IND Type B review…
Mydecine Innovations (MYCO.NE) announced they are filing a new patent for their MDMA-like compounds. In the press release Mydecine writes that “this expansive patent would allow Mydecine to scale…
Revive Therapeutics (RVV.C) has provided an update on the Company’s US Food and Drug Administration (FDA) Phase 3 clinical trial to evaluate the safety and efficacy of bucillamine in…
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has reviewed its pre-IND request for a Type B review of the Company’s Covid-T™ program.   “We…
Medexus Pharmaceuticals (MDP.V) announced that they’re making their Triamcinolone Hexacetonide (TH) Injectable Suspension, USP (20 mg/ml) available in the United States through the FDA’s CDER Drug Shortage program in…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Perimeter Medical Imaging AI (PINK.V) announced that the US Food and Drug Administration (FDA) has granted them a Breakthrough Device Designation for their Optical Coherence Tomography (OCT) Imaging System…
Helius Medical Technologies (HSM.T) subsidiary, Helius Medical, received the go-ahead from the Food and Drug Administration to take their portable neuromodulation stimulator (PoNS) device to market.   The PoNS…
Revive Therapeutics (RVV.C) provided an update on their FDA Phase III clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate Covid-19.  …